Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (OMIM 201910) represents 90--95% of all CAH cases[@b1][@b2][@b3]. This autosomal recessive disorder, which is the most frequent inborn error of metabolism, has a broad spectrum of clinical forms, ranging from severe or classical, to mild late onset or non-classical (NC). The classical form includes the salt-wasting (SW) and simple virilizing (SV) of early onset. Girls with classical CAH are typically born with ambiguous genitalia. Patients with NC CAH exhibit clinical manifestations of hyperandrogenism.

The gene encoding 21-hydroxylase, *CYP21A2* is mapped to the short arm of chromosome 6 (6p21.3), within the human leukocyte antigen (HLA) complex, in the so-called RCCX module. Approximately two thirds of the chromosomes analyzed have a duplicated RCCX module that includes a genomic DNA segment composed of the pseudogenes *RP2, CYP21A1P, TNXA*, and a second active copy of the *C4* (long or short) gene[@b4][@b5]. *CYP21A1P* shares 98% sequence identity with *CYP21A2*. Due to the high degree of sequence identity between the gene and its pseudogene, most of the disease-causing mutations described in 21-hydroxylase deficiency are likely to be the consequence of non-homologous recombination or gene conversion events[@b6][@b7]. Although most of the patients carry *CYP21A1P*-derived mutations, an increasing number of naturally occurring mutations have been found in disease-causing alleles (see: <http://www.hgmd.cf.ac.uk> for details).

Mutations in the *CYP21A2* gene cause varying degrees of 21-hydroxylase activity loss. *In vitro* studies revealed that mutations leading to a complete inactivation of 21-hydroxylase are usually associated with the SW phenotype. Mutations that reduce enzyme activity close to 2% cause the SV phenotype, whereas those with a residual enzymatic activity in the range of 10% to 60% result in the mild NC CAH phenotype. In addition, a great number of patients are compound heterozygotes carrying different *CYP21A2* mutations on each allele, and their phenotypes depend on the milder gene defect[@b8].

21-hydroxylase belongs to the cytochrome P450 protein family, a huge and diverse family found in bacteria, archaea and eukaryotes. In humans, there are 57 genes and more than 59 pseudogenes grouped in 18 families and 43 subfamilies, all with a high sequence identity[@b9]. 21-hydroxylase displays microsomal localization[@b10] and, like other microsomal P450s, this enzyme accepts electrons provided by a NADPH-dependent P450 oxidoreductase (POR), reducing molecular oxygen and hydrolyzing substrates. This enzyme has 494--495 aminoacids with a molecular weight of 52 kDa[@b11][@b12].

Over the last few years, much progress has been made towards predicting protein stabilities and correlating them to protein activities[@b13][@b14][@b15][@b16][@b17]. Homology modeling and fast energetic calculations have emerged as useful tools to evaluate, through structure-based methods, the impairment of protein stability. Human 21-hydroxylase models have been built based on the available low homology CYP protein families[@b13][@b16].

With the aim of predicting the effect of newly uncharacterized mutations with improved accuracy, we have developed and evaluated a procedure based on the high identity bovine and human templates[@b18][@b19]. Using bioinformatic tools and either the human crystal structure or a model based on the bovine CYP21A2 counterpart, we initially classified all mutants in coding regions according to their putative role in protein dysfunction and/or location in the structure and focused our analysis on those affecting protein stability. Using this approach, we estimated *in silico* the residual activity of mutants that lack functional assays. Furthermore, we estimated the effect of double mutations/SNPs, located *in cis,* on P450CYP21 protein stability. In addition, we propose the putative pathogenic effect of five novel mutations, p.L107Q, p.L122R, p.R132H, p.P335L and p.H466fs, found in 21-hydroxylase deficient patients of our cohort.

Results
=======

Survey of CYP21A2 reported variants
-----------------------------------

With the aim of predicting the effect of uncharacterized mutations, we initially performed an extensive survey of mutations and SNPs modifying the coding sequence of the gene (n = 343). Using either the human crystal structure (PDB ID:4Y8W) or a model based on the high identity crystal structure from the bovine protein (PDB ID:3QZ1), the variants were classified according to their proposed effect on protein dysfunction and/or location in the structure ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Table S1](#S1){ref-type="supplementary-material"}).

Correlation of protein stability and CYP21A2 activity
-----------------------------------------------------

We focused our analysis on mutations assumed to be involved in protein stability (148 variants), under the hypothesis that protein destabilization affects enzymatic activity. Of these, we initially selected variants with experimental enzymatic activity reported until 2013 (n = 30, see [Table S1](#S1){ref-type="supplementary-material"}). Using the FoldX algorithm, the predicted free energy of each of the mutants relative to the wild type counterpart (∆∆G) was plotted against the natural logarithm (ln) of the *in vitro* activity as previously reported[@b16]. As shown in [Fig. 1](#f1){ref-type="fig"}, a good correlation between FoldX's predictions and experimental activity was obtained. Correlation was higher when using the bovine-based model (R^2^ = 0, 79) than for the human crystal structure (R^2^ = 0, 60). As a reference, we compared the *in vitro* activity for an overlapping set of mutants with the predicted stability reported by two previous models, obtaining a R^2^ = 0, 48 (n = 13) with the rabbit CYP2C5[@b13] and a R^2^ = 0, 68 (n = 7) with the bovine CYP21A2[@b20].

To validate our method, we estimated the *in silico* enzymatic activity of mutants with experimental activities reported from 2014 up to the present[@b21][@b22][@b23][@b24], excluding residues known to impair protein function independently of protein stability. To accomplish this, the predicted residual activity after calculation of ∆∆G was compared with the activity reported in functional assays and with the patients' phenotypes. As shown in [Table 1](#t1){ref-type="table"}, in 5 out of 10 mutations the predicted *in silico* residual activity was similar to the experimental results. Nevertheless, a close look at the remaining 5 mutations revealed that, contrary to the *in vitro* assay results, the *in* silico predicted p.P45L activity may correlate better with the patient's phenotype ([Table 1](#t1){ref-type="table"}). For the p.K102R variant, the predicted activity using the bovine-based template might be related to a NC CAH allele. Nevertheless, the *in silico* activity predicted using the human crystal structure is consistent with the fact that p.K102R has long been considered a common polymorphism[@b25]. For the p.M150R variant, both computed *in silico* activities may predict severe alleles, whereas discordant results were reported *in vitro (*17%, NC; 4%, SV). Finally, for the p.M283V variant the values of the *in silico* activities were twice the residual enzymatic activities found *in vitro*. Nevertheless, both are activities found in mild alleles.

*In silico* prediction of residual enzymatic activity
-----------------------------------------------------

Using this procedure we predicted the *in silico* residual enzymatic activity of 32 CYP21A2 mutations[@b20][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43] that lack functional assays and are putatively involved in protein destabilization. The predicted activities were calculated from the linear fit based on the bovine template, which showed a better correlation with the experimental activities (see above). As shown in [Table 2](#t2){ref-type="table"}, in 10 mutations, the *in silico* activity was in accordance with the allele type expected from the observed phenotype. However, in 9 of 32 mutations such correlation could not be assessed due to the lack of information of the mutation in the homologous allele and/or the patient's phenotype.

We extended our approach to the *CYP21A2* variants (n = 76) deposited as SNPs in public databases ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Table S2](#S1){ref-type="supplementary-material"}). All the predicted enzymatic activities above 75% were considered to be non-pathogenic. Fifty-two SNPs disclosed no biological implications.

Stability prediction of double mutants/SNPs located *in cis*
------------------------------------------------------------

We aimed to identify CYP21A2 variants in which two mutations can combine to generate a severe effect and to identify variants presenting a synergistic effect, namely, improving or impairing the enzymatic activity to a greater extent than expected by the sum of each individual mutation. To this end, we analyzed the effect of two allelic variants (mutation-mutation, mutation-SNP or SNP-SNP) found *in cis* on protein stability.

Of all possible combinations for mutant-mutant or mutant-SNPs, we considered the following scenarios: 1) there is a trivial situation in which both mutations, as well as their addition, are above the cut-off value (1.6 kcal/mol), and consequently we expect a pathogenic effect (most cases reported, not shown); 2) another possibility is that neither of the mutations nor SNPs exceeds the cut off value but their sum indeed does, in which case we predict pathogenicity derived from impaired enzymatic activity ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Tables S3A](#S1){ref-type="supplementary-material"} and [S4A); 3](#S1){ref-type="supplementary-material"}) and finally, when only one of the mutations exceeds the cut off value but combined with another mutation or SNP their sum drops below the cut-off value, in which case we predict a non-pathogenic effect ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Tables S3B](#S1){ref-type="supplementary-material"} and [S4B](#S1){ref-type="supplementary-material"}).

Interestingly, FoldX allowed us to identify synergistic effects (either positive or negative) that may suggest a change in the classification of effect of the mutation. For example, a negative synergistic effect is one in which the sum of the effects of two mutations/SNPs exceeds the cut off, but their combined analysis by FoldX results in a lower value ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Tables S3C,D](#S1){ref-type="supplementary-material"} and S4C,D), whereas a positive synergistic effect is one in which the sum of two mutations or SNPs does not exceed the cut-off value, but their combined analysis with FoldX does ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Table S4E](#S1){ref-type="supplementary-material"}). Strikingly, there are cases in which neither of the mutations, nor their sum, exceeds the cut-off value, but FoldX nevertheless predicts a synergistic effect and thus, pathogenicity ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Table S4F](#S1){ref-type="supplementary-material"}).

When SNP-SNP double mutants were analyzed, none of them presented values above the cut-off (not shown). The combination of p.K102R with p.S268T, each with a small contribution to destabilization (0.81 and 0.74 kcal/mol, respectively), did however result in a value close to that of the cut-off (1.55 kcal/mol).

Structure-based predicted effect of novel mutants
-------------------------------------------------

We analyzed the putative structural and functional effects of 5 novel mutations, p.L107Q, p.L122R, p.R132H, p.P335L and p.H466fs, found in patients from our cohort (see [Supplementary Information Table S5](#S1){ref-type="supplementary-material"} for details on patients phenotypes and genotypes). None of these novel variants were found in the 1000 Genome Database. In addition, all but one, p.P335L, are located in CYP21 protein residues that are highly conserved throughout mammalian species ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Figure S1](#S1){ref-type="supplementary-material"}).

[Figure 2](#f2){ref-type="fig"} shows the structural analysis of the novel point mutations on the human protein. As shown, the side chain of L107 is located very close (4.31Å) to the propionate moiety of the heme group ([Fig. 2D](#f2){ref-type="fig"}). The introduction of glutamine's positive charge might disrupt hydrophobic interactions that stabilize the heme group. The mutation in residue 122 replaces a hydrophobic leucine with a bulky and positively charged arginine residue, thus modifying the electrostatic potential surface of the protein. Conversely, the change of a positively charged arginine to a histidine residue in position 132 might cause a decrease in the density of positive charge on the protein's surface ([Fig. 2B,C](#f2){ref-type="fig"}). Both changes are positioned in regions where several amino acids have been suggested to interact with the POR[@b13]. Thus, we expect changes in electrostatic potential to significantly affect protein-protein interactions. Residue P335 ([Fig. 2E](#f2){ref-type="fig"}) is located in a loop between helices K and L[@b19]. The change from a proline residue to a leucine does not introduce a charge modification in the region and neither heme/ligand nor POR interactions are involved, although a spatial displacement of the loop upon mutation cannot be ruled out. We classified this mutation as being putatively involved in protein stability. We found a ∆∆G of −2.16 ± 0.15 kcal/mol for the bovine-based template and consequently the *in silico* predicted activity is ≥100%. Similar results were obtained when modeling residues involved in novel point mutations using the bovine template ([Supplementary Information](#S1){ref-type="supplementary-material"}, [Figure S2](#S1){ref-type="supplementary-material"}).

Lastly, the p.H466fs mutation causes a frameshift in the carboxy-terminus of the protein, resulting in a completely different tract of 59 residues and introducing 27 additional amino acids to the protein. Consequently, this variant cannot be accurately modeled by the present approach; notwithstanding, a nonfunctional protein could be expected.

Discussion
==========

The adrenocortical 21-hydroxylase is one of the key enzymes in glucocorticoid and mineralocorticoid biosynthesis, and mutations in the *CYP21A2* gene cause the CAH as a result of 21-hydroxylase deficiency. Most of the reported mutations in the coding region result in aminoacid substitutions that may disturb essential functional and structural motifs of the protein (<http://www.hgmd.cf.ac.uk>). Activity impairment will also be evident when the mutation affects the correct folding and stability of the protein and thus its availability in the cell. Furthermore, an even more subtle case can be envisioned in which the protein's activity is impaired by mutations that alter protein dynamics and thus, its behavior in the cell.

There are several examples of structure-based studies correlating specific aminoacidic change in CYP21A2 and other proteins with the severity of the encoded allele. CYP21A2 studies were initially based on low-identity templates[@b13][@b16], and then repeated when a high-identity bovine protein[@b18] was made available[@b20]. Recent publication of the human CYP21A2 crystal structure[@b19] encouraged us to improve and expand our analysis by including this structure as template.

It is worth noting that most of our test data sets are obviously biased towards mutations with a deleterious effect as they come from clinical cases. For a subset of these mutations, functional assays have been performed, demonstrating their involvement in the pathogenicity of the disease. Nevertheless, for some of the reported variants, no information is available.

21-hydroxylase deficiency is a recessive disorder and most of the patients are compound heterozygotes with different mutations in each allele. Thus, a detailed description of the putative severity of a mutant protein must be carefully considered within the context of the mutation on the homologous chromosome and the patient's phenotype.

Considering a protein length of 494--495 amino acids for the human CYP21 and only 20 different residues, the number of possible mutants is between 494[@b20] and 495[@b20]. So far, only 210 of them have been seen in patients and, among these, approximately 33% are assumed to be involved in protein stability and could be evaluated by our method. In addition, 76 allelic variants presumably involved in protein destabilization were found in individuals from the general population, and their putative implications on protein activity are not known. We believe that activity prediction for variants could be useful to partially understand their pathophysiological implications. This is particularly relevant in the case of mild double mutants *in cis* in which the combined effect is unknown but may be predicted. In the future, this method could also be extended to several excluded positions depending on the development of algorithms capable of readily predicting heme and ligand interactions, and the availability of templates with different ligands (including interacting partners, such as POR). This sort of extension has been implemented to successfully assess protein-DNA interactions[@b15][@b44].

It is expected that both the sequence identity and structural resolution improve energetic predictions. Surprisingly, in our analysis, stability calculations based on the bovine crystal structure resulted in a better correlation to experimental measurements than those based on the human counterpart. We hypothesize that these unexpected results could be related to the experimental conditions in which each structure was obtained. X-Ray diffraction crystallography provides a picture of the lowest energy conformation for a given protein, usually biasing our interpretation to a unique and rigid entity. Furthermore, proteins that interact with several ligands often adopt different conformations depending on the binding partner. In such cases, it is useful to have several structures with the different ligands or NMR data to further understand the conformational states of the system. In our study we have worked with only two structures: the bovine protein bound to 17-hydroxyprogesterone (17-OHP) and the human CYP21A2 bound to progesterone, each of which may represent a biased conformation that may in turn affect the structure-based energetic calculations. Thus, considering that proteins are dynamic entities that fluctuate and interact with several ligands in the cell, the overall behavior may be better grasped by a structure that could represent protein fluctuations around the energetic minimum rather than a structure representing the minimum itself as observed in the static crystal.

Remarkably, when we validated our method taking into account the most recent mutations with functional assays reported, half of them were in agreement with *in vitro* residual activities. Only 1 out of the 10 variants, p.R149C, was found to be a completely discordant result, and contrary to the functional assays, some of the *in silico* results may better represent the patient's phenotype.

We then proceeded to predict stability and associated activity for all reported mutations or SNPs not expected to be involved in other processes except for protein stability. As expected, most of the SNPs described in population-based studies were found to have no biological implications. Moreover, when a correlation of the *in silico* results and the expected activity from the observed phenotype could be assessed, we found consistency in 10 of the variants analyzed. These results reinforce our approach as a useful tool for predicting residual activities of uncharacterized allelic variants.

A number of 21-hydroxylase deficient alleles have been reported with two mutations occurring *in cis*. Thus, we extended our method to analyze CYP21A2 variants that can combine to generate a severe and/or synergistic effect, including those reported to have no biological effect on protein activity (SNPs). Though there are very few experimental results of the final residual activity of *in-cis* double mutants to compare with, we predicted several combinations to have a severe and/or synergistic effect of a rather small magnitude. Strikingly, the combination of p.K102R with p.S268T, two variants classified individually as non-pathogenic in experimental assays[@b24][@b45] reaches a destabilization value close to the cut-off. This is particularly important, since both variants are described in a great number of individuals from the general population[@b46]. Though the absence of mutations in patients diagnosed with 21-hydroxylase deficiency has been described previously, the putative pathogenic effect of two SNPs *in cis* has yet to be considered. Indeed, several authors have suggested that p.S268T could result in a decreased enzymatic activity when presented *in cis* with another polymorphic variant[@b47][@b48].

The structure-based approach enables us the prediction of the effect of mutations that modify protein stability. For mutations impairing activity by other means, it is necessary to perform *in vitro* activities or develop computational tools that can explicitly model interactions with ligands (e.g. substrates, the heme group or other proteins). From the set of newly described mutants, only p.P335L was expected to affect stability. Nevertheless, we found that the predicted activity of this variant should be close to that of the wild-type protein since no destabilization change was found. Sequence comparisons demonstrated variability in the 335 residue throughout CYP21 proteins of different mammalian species. Indeed, a leucine residue is located at this position in the mouse and the rat proteins. In addition, *in vitr*o studies have suggested that the presence of two mild mutations *in cis* is generally associated with a severe impairment of enzymatic activity[@b23][@b49][@b50][@b51]. However, the patient with the p.P335L variant presented a NC phenotype, carrying a large gene conversion/deletion of the *CYP21A2* gene on the homologous allele (null allele) and the mild p.V281L mutation *in cis.* Taken together, these observations prompted us to suggest that this allelic variant may not influence the residual activity of the protein, in agreement with the *in silico* predictions. However, caution should be taken considering that a significant stabilization was found for this variant and a large stabilization could also affect protein degradation or its dynamics, and thus protein function.

In the post-genomic and personalized medicine era a large amount of genetic information is expected to accumulate. The development of an efficient tool to analyze this information is of utmost importance. In particular, connecting sequence information to phenotypic effects is an ongoing effort that could assist physicians in the near future. So far, most of the information on mutants is biased towards pathological effects but sooner or later an immense amount of uncharacterized variants will be described with the massive sequencing approaches currently underway. Until statistics or other methods can be used with enough confidence, we propose that *in silico* activity prediction using structure-based analysis could be a valuable tool, being particularly relevant in the case of double variants occurring *in cis*.

Materials and Methods
=====================

Ethical Approval
----------------

All the procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all patients and parents involved in this work. The study was approved by the ethics committee of the Administración Nacional de Laboratorios e Institutos de Salud (ANLIS), Buenos Aires, Argentina.

*CYP21A2* genotyping
--------------------

Details on methods in mutation genotyping and sequence alignments are presented in [Supplementary Information](#S1){ref-type="supplementary-material"}.

Survey of allelic variants and mutations in human CYP21A2
---------------------------------------------------------

Mutations and allelic variants in the coding region of the CYP21A2 were extracted from the Human Cytochrome P450 Allele Nomenclature database ([www.cypalleles.ki.se](http://www.cypalleles.ki.se)), and from the bibliography. In addition, database of single nucleotide polymorphisms (SNPs) and multiple small-scale variations that include insertions/deletions, microsatellites and non-polymorphic variants (<http://www.ncbi.nlm.nih.gov/projects/SNP/>)[@b52], as well as the 1000 Genome Database[@b53] were also consulted. When available, the *in vitro* activity for progesterone (P) and/or 17-hydroxyprogesterone (17-OHP) were included. When more than one activity was reported for the same mutation, we considered references that provided measurements of residual activity exclusively in *ex vivo* systems (in COS1 or COS7 cells). In addition, when possible, the most accurate, newest and better related to patient's phenotype was preferred. The full list of mutations/SNPs considered is listed in [Supplementary Information Table S1](#S1){ref-type="supplementary-material"}.

Model building and assessment
-----------------------------

In addition to the human crystal (PDB ID: 4Y8W), a model of the human CYP21A2 protein based on the structure of the bovine CYP21A2 (PDB ID: 3QZ1) was generated using MODELLER version 9.11[@b54] including heme cofactor explicitly. Amino acid sequence was taken from UniProt (NP_000491.4) while alignments were performed with MEGA 4 software[@b55]. A significant improvement of the model was obtained by manually displacing L129 in the automatic alignment and iterative loop refinement. The use of multiple templates of other proteins of the CYP family did not improve the model (not shown). Model's quality was assessed by DOPE[@b56], QMEAN Z-scores[@b57] and Ramachandran plots[@b58]. Protein model is available at [www.modelarchive.org/project/index/doi/ma-anifj](http://www.modelarchive.org/project/index/doi/ma-anifj).

*In silico* mutagenesis
-----------------------

Mutations were generated and analyzed using FoldX 3.0 Beta 5.1 (foldx.crg.es)[@b59]. Repair PDB FoldX command was used to optimize the total energy of the protein to FoldX's force field before mutations were done. Mutagenesis was carried out using the BuildModel FoldX command, and each mutation was calculated five times.

Variant classification
----------------------

Variants were classified according to the following categories: nonsense, indel, deletion or duplication, heme or ligand interaction, POR interaction, protein degradation, Meander and the ERR-Triad, or stability ([Table S1](#S1){ref-type="supplementary-material"}). For those in the latter group, we proceeded to calculate protein stabilities and correlated them with reported *in vitro* activities (see below). Some residues were not classified into the former categories, but were excluded instead due to a poor structure resolution of the corresponding templates.

Residues were considered to be involved in heme or ligand binding when the amino acid is within 5 Angstroms and pointing towards heme/ligand. Residues were considered to interact with POR according to Robins *et al*.[@b13], or when charged residues (Arginine and Glutamic acid) were found in a close proximity and exposed to the same surface than those reported by Robins *et al*.[@b13], namely residues R124, E140, E320, R341, R356, R366, R369, R431 and R444.

Stability calculations
----------------------

Protein stabilities were calculated using FoldX's Stability command, and ∆∆G values were estimated as the difference between the energy of the wild type protein and the average of five replicas for each point mutation. A threshold of 1, 6 kcal/mol was considered, as it corresponds to twice the standard deviation calculated with FoldX. We considered values above this threshold to significantly destabilize a protein. Mutations located in functional residues (e.g. those involved in disulfide bridge or in heme, substrate or ligand binding) were excluded from the stability analysis as their effects on protein activity are influenced by other variables besides protein stability. To favor wild type conformation, all residues involved in ligand or heme interactions where fixed when optimizing the structures to FoldX force field.

Statistical analyses
--------------------

The predicted free energy of each of the mutants relative to the wild type counterpart (∆∆G) was plotted against the natural logarithm (ln) of the *in vitro* activity. Mutants with experimental activities around 0% of the wild type presented destabilization values around 5, 5 kcal/mol. Thus, this value was considered as the maximum one for the fitting, even when FoldX predicts larger values (mutants L142P and L166P). The predicted activities of those mutants lacking functional assays were derived from the fitting of the abovementioned correlation.

Statistical analyses were performed using the Infostat V.11 (<http://www.infostat.com.ar/?lang=en>) and GraphPad Prism V. 5.01 Softwares (<http://www.graphpad.com/scientific-software/prism/>). Spearman's correlation coefficient was used to determine a monotonous relation between ∆∆G and the ln of the activity. Permutation test was applied to evaluate its statistical significance. The parameters of the linear regression were calculated by the least squares method and the statistical significance of the regression line's slope by a permutation test. A p \< 0.05 was considered significant.

Double mutant/SNP effect
------------------------

Only those variants with a reported *in vitro* activity and classified as putatively involved in protein stability were analyzed. Double mutants/SNPs *in cis* were generated as described above. Synergistic effect in those cases was assessed by comparing the estimated ∆∆G of the double mutant to the sum of both single mutants. When there is no synergy, the difference between them tends to zero.
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![Correlation between experimental activities and predicted stabilities for Human and Bovine based templates.\
A total of 30 mutants in human P450CYP21A2 protein with *in vitro* functional studies published up to 2013 were analyzed using either our own generated three-dimensional structure of CYP21 based on the bovine template PDB ID: 3QZ1 (**A**) or the human crystal structure PDB ID: 4Y8W (**B**). Only residues evaluated to impair protein function by means of protein stability were included. The predicted free energy change (∆∆G) upon mutation was plotted against the natural logarithm (ln) of the residual enzymatic activity on 17-OHP (**A**) or Progesterone (**B**) as substrates. A value of 5, 5 kcal/mol was considered as the maximum one for the fitting as higher destabilization will not impair activity below 0%. Spearman's correlation coefficients were −0.894 and −0.829 for the 3QZ1 model and 4Y8W, respectively. These values were statistically significant (p \< 0.001, permutation test). The values of the regression line slopes were also statistically significant (p \< 0.001) ΔΔG is expressed in kcal/mol.](srep39082-f1){#f1}

![Structural analysis of novel point substitution in the human CYP21A2.\
(**A**) Cartoon representation of the residues involved in the novel point mutations found. Residues are labeled and highlighted by orange spheres. Heme cofactor is depicted in sticks. Residues involved in POR interaction are depicted in blue. (**B**) and (**C**) Differences in electrostatic surface upon mutations. Electrostatic surfaces of the wild type L122 and R122 as well as of the R122 and H132 mutants are represented. Residues are indicated by arrows. Acidic regions are depicted in red and basic ones in blue. (**D**) Cartoon representation of the residue L107 in the structure. Residue L107 (in light blue sticks) points towards the heme's propionate moiety at a distance of 4.31 Å. HEM: heme group. P: Progesterone. (**E**) Cartoon representation of the residue P335 in the structure. Residues located nearby in the 3D structure are also shown.](srep39082-f2){#f2}

###### Comparison of *in vitro* and *in silico* predicted activities of aminoacidic variants in CYP21A2 presumed to be involved in protein stability published since 2014.

  Mutation    *In vitro* activity ± SD   *In silico* activity   Patient's second mutation (REA%)   Patient's phenotype    Reference            
  ---------- -------------------------- ---------------------- ---------------------------------- --------------------- -------------- ------- --------
  p.P45L              105 ± 10                    ND                          0.74                        1.46                ND         SV     [@b21]
  p.K102R            119.7 ± 25                   ND                         63.16                        ≥100                ND         NA     [@b21]
  p.L122P            1.4 ± 2.1                −1.9 ± 5.2                      0.11                        0.25           Deletion (0)    SW     [@b22]
  p.R149C           35.8 ± 14.6              47.3 ± 12.9                      ≥100                        ≥100           p.V281L (60)    NC     [@b23]
  p.M150R            17.7 ± 1.9               4.6 ± 1.9                       0.9                          4.4                N          PB     [@b22]
  p.A159T           126.6 ± 29.9                  ND                          ≥100                        ≥100                N          AD     [@b21]
  p.V211M           99.5 ± 32.4                   ND                          ≥100                        ≥100                ND        SV/NC   [@b21]
  p.A265S              90 ± 9                  104 ± 15                       ≥100                        ≥100                N          NA     [@b24]
  p.M283V            16.2 ± 9.3                 19 ± 7                        41.8                        38.14          Deletion (0)    NC     [@b23]
  p.M473I              85 ± 7                  66 ± 12                        ≥100                        64.12          p.V281L (60)    NC     [@b24]

*In silico* enzymatic activities were calculated from the fitting of the bovine based model and from the human crystal ([Fig. 1](#f1){ref-type="fig"}) using the estimated **∆∆**Gs of each of the mutants ([Table S1](#S1){ref-type="supplementary-material"}). *In vitro* and *in silico* enzymatic activities are expressed in percentage relative to the wild type protein considered as 100%. *In vitro* enzymatic activities, patients' second mutation and phenotypes are those reported in the bibliography. 17-OHP: 17-hydroxyprogesterone. P: Progesterone. REA: Residual enzymatic activity. ND: Not determined. N: Normal; NC. Nonclassical; SV: Simple virilizing; SW: Salt wasting; NA: Not Affected; PB: Premature Pubarche; AD: Addison Disease.

###### *In silico* predicted residual activity of CYP21A2 stability mutants lacking functional assays.

  Variant      Patient's second mutation (% REA)     Patient's phenotype   Expected activity of the variant    ∆∆G    *In silico* activity (%)   Reference
  --------- --------------------------------------- --------------------- ---------------------------------- ------- -------------------------- -----------
  p.H38L                      NA                             NA                           ?                   −1.64             100               [@b26]
  p.Y47C                      NA                             NA                           ?                   −1.64             100               [@b27]
  p.Y59N                      NA                             CL                          0--5                 2.54              4.4               [@b28]
  p.V69L     p.\[Q318;.R356\] (0) pH62L *in cis*\*           SV                         5--60                 1.47              22.5              [@b29]
  p.S113Y                p.V281L (60)                        NC                         0--60                 0.79              63.3              [@b30]
  p.S113F                     NA                             NA                           ?                   1.05              42.6              [@b20]
  p.Q144P                p.P482fs (ND)                       SW                           0                   0.61              83.2              [@b29]
  p.F164S                 p.I172N (2)                        SV                          0--5                 1.37              26.2              [@b29]
  p.S165P                 p.I172N (2)                        NC                         10--60                4.94              0.1               [@b31]
  p.T168N              Chimeric gene (0)                     NC                         10--60                3.41              1.2               [@b32]
  p.V211L                     NA                             N?                           ?                   −0.91             100               [@b33]
  p.E238K                     NA                         4 SW, 1 NC                   0^**\#**^               −0.33             100               [@b34]
  p.V249A                     NA                              N                          100                  0.45              100               [@b35]
  p.L261P       c.290-13A/C\>G^**\*\***^ (0--2)              SW                           0                   8.95              0.01              [@b36]
  p.M283L                p.V281L (60)                        NC                         0--60                 −0.3              100               [@b37]
  p.S301Y       c.290-13A/C\>G^**\*\***^ (0--2)              NC                         10--60                12.31             0.00              [@b38]
  p.V304E       c.290-13A/C\>G^**\*\***^ (0--2)              SW                           0                   2.44              5.1               [@b29]
  p.V305D                     NA                             NA                           ?                   0.99              46.6              [@b20]
  p.F306V                     NA                             NA                           ?                   1.87              12.2              [@b20]
  p.L307V                Deletion (0)                        NC                         10--60                 2.8              2.9               [@b30]
  p.R316L                p.V281L (60)                        NC                         0--60                 0.03              100               [@b30]
  p.L317M       c.290-13A/C\>G^**\*\***^ (0--2)              NC                         10--60                −0.8              100               [@b39]
  p.L317V                      N                          NC^**§**^                       ?                   2.42              5.3               [@b40]
  p.L321P                     NA                             NA                           ?                   9.84              0.0               [@b20]
  p.G381S                     NA                             NA                           ?                   3.51              1.0               [@b20]
  p.N387K               p\. V281L (60)                       NC                         0--60                 7.55              0.0               [@b41]
  p.F404S                p.F404S (ND)                        SW                           0                   5.34              0.06              [@b42]
  p.F404L                p.V281L (60)                        NC                         0--60                 2.51              4.6               [@b30]
  p.T450P                p.T450P (ND)                        SW                           0                   9.35              0.0               [@b42]
  p.P459H        p.\[ClEx6; Q318X; A391T\] (0)               SV                          2--5                 4.44              0.2               [@b43]
  p.P459S                Chimeric Gene                       SV                          2--5                 2.68              3.6               [@b32]
  p.P459L       c.290-13A/C\>G^**\*\***^ (0--2)              SV                          0--5                 1.29              29.5              [@b29]

*In silico* predicted activities of mutants lacking functional assays were compared with the expected ones. Expected activity was established considering the residual activity of the mutation on the homologous allele and/or the patient's phenotype when available. *In silico* enzymatic activities were calculated from the fitting based on the bovine template using the estimated **∆∆**G of each of the variants ([Table S1](#S1){ref-type="supplementary-material"}). Activities are expressed relative of the wild type protein (100%). \*According to functional assays, p.H62L mutation was classified as a mild mutation. Nevertheless, several alleles were described having another mild mutation *in cis* with decreased enzymatic activities most likely related to the SV form of the disease[@b50][@b60]. ^**\*\***^c.290-13A/C\>G mutation creates a new acceptor splice site. Patients bearing this mutation have been described presenting either a SW or a SV phenotype[@b8]. ^\#^The classification of the expected activity for this variant was based on the fact that 4/5 patients presented a SW phenotype. ^**§**^The patient described by Byounga *et al*.[@b40], disclosed a 17-OHP post ACTH value of 6, 67 ng/mL. According to the current inclusion criteria, patients would be classified as presenting a NC form of the disease when the post ACTH test is at least 10 ng/mL[@b61]. REA: Residual enzymatic activity. NA: Not available, ND: Not determined; N. Normal; NC. Nonclassical; SV: Simple virilizing; SW: Salt wasting; CL: Classical; N: Normal; ClEx6: Cluster Exon 6 mutations. ?: Insufficient data to estimate the expected enzymatic activity.
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